Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody

Nuclear Medicine and Biology

Volumn 39, Issue 5, 2012, Pages 645-651

  Liu, Guozheng ^a   Dou, Shuping ^a   Akalin, Ali ^a   Rusckowski, Mary ^a   Streeter, Philip R ^b   Shultz, Leonard D ^c   Greiner, Dale L ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c JACKSON LABORATORY   (United States)

Author keywords

Anti human islet antibody; Islet cell imaging; Pretargeting; T NT ratios

Indexed keywords

INDIUM COMPLEMENTARY PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER IN 111; PANCREAS ISLET CELL ANTIBODY; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER PANCREAS ISLET CELL ANTIBODY; RADIOISOTOPE; TECHNETIUM COMPLEMENTARY PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER TC 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BIOACCUMULATION; CELL INTERACTION; CONTROLLED STUDY; DRUG DISTRIBUTION; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; ISOTOPE ANALYSIS; ISOTOPE LABELING; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; RADIOACTIVITY; RADIOISOTOPE DISTRIBUTION; TARGET CELL; TARGET ORGAN;

ANIMALS; ANTIBODIES; CELL LINE; HUMANS; INDIUM RADIOISOTOPES; INSULIN-SECRETING CELLS; ISOTOPE LABELING; MICE; MORPHOLINOS; SKIN;

EID: 84862784188     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.12.001     Document Type: Article

References (33)

1. Paty B.W., Bonner-Weir S., Laughlin M.R., McEwan A.J., Shapiro A.M. Toward development of imaging modalities for islets after transplantation: insights from the National Institutes of Health Workshop on Beta Cell Imaging. Transplantation 2004, 77:1133-1137.
2. Souza F., Freeby M., Hultman K., et al. Current progress in noninvasive imaging of beta cell mass of the endocrine pancreas. Curr Med Chem 2006, 13:2761-2773.
3. Moore A. Advances in beta-cell imaging. Eur J Radiol 2009, 70:254-257.
4. Malaisse W.J., Louchami K., Sener A. Noninvasive imaging of pancreatic beta cells. Nat Rev Endocrinol 2009, 5:394-400.
5. Brom M., Andrazojc K., Oyen W.J., Boerman O.C., Gotthardt M. Development of radiotracers for the determination of the beta-cell mass in vivo. Curr Pharm Des 2010, 16:1561-1567.
6. Martinic M.M., von Herrath M.G. Real-time imaging of the pancreas during development of diabetes. Immunol Rev 2008, 221:200-213.
7. Villiger M., Goulley J., Martin-Williams E.J., Grapin-Botton A., Lasser T. Towards high resolution optical imaging of beta cells in vivo. Curr Pharm Des 2010, 16:1595-1608.
8. Medarova Z., Moore A. MRI as a tool to monitor islet transplantation. Nat Rev Endocrinol 2009, 5:444-452.
9. Evgenov N.V., Medarova Z., Dai G., Bonner-Weir S., Moore A. In vivo imaging of islet transplantation. Nat Med 2006, 12:44-48.
10. Antkowiak P.F., Tersey S.A., Carter J.D., et al. Noninvasive assessment of pancreatic beta-cell function in vivo with manganese-enhanced magnetic resonance imaging. Am J Physiol 2009, 296:E573-E578.
11. 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med 2009, 50:382-389.
12. 18F-FP-({thorn})-DTBZ: a potential PET ligand for studying diabetes mellitus. J Nucl Med 2008, 49:1171-1176.
13. 2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 2006, 47:2025-2033.
14. Körner M., Stöckli M., Waser B., Reubi J.C. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007, 48:736-743.
15. Karacay H., Brard P.Y., Sharkey R.M., et al. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res 2005, 11:7879-7885.
16. Sharkey R.M., Cardillo T.M., Rossi E.A., et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 2005, 11:1250-1255.
17. Pagel J.M., Hedin N., Subbiah K., et al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 2003, 101:2340-2348.
18. Subbiah K., Hamlin D.K., Pagel J.M., et al. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med 2003, 44:437-445.
19. Magnani P., Paganelli G., Modorati G., et al. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J Nucl Med 1996, 37:967-971.
20. Liu G., Dou S., Cheng D., et al. Human islet cell MORF/cMORF pretargeting in a xenogeneic murine transplant model. Mol Pharm 2011, 8:767-773.
21. de la Tour D., Halvorsen T., Demeterco C., et al. Beta-cell differentiation from a human pancreatic cell line in vitro and in vivo. Mol Endocrinol 2001, 15:476-483.
22. null mice engrafted with mobilized human hematopoietic stem cell. J Immunol 2005, 174:6477-6489.
23. Dorrell C., Abraham S.L., Lanxon-Cookson K.M., Canaday P.S., Streeter P.R., Grompe M. Isolation of major pancreatic cell types and long-term culture-initiating cells using novel human surface markers. Stem Cell Res 2008, 1:183-194.
24. Hnatowich D.J., Layne W.W., Childs R.L., et al. Radioactive labeling of antibody: a simple and efficient method. Science 1983, 220:613-615.
25. Liu G., Liu C., Zhang S., et al. Investigations of technetium-99m morpholino pretargeting in mice. Nucl Med Commun 2003, 24:697-705.
26. Liu G., Dou S., Pretorius P.H., Liu X., Rusckowski M., Hnatowich D.J. Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF. Eur J Nucl Med Mol Imaging 2008, 35:272-280.
27. 111In-DTPA morpholino oligomer for low abdominal accumulation. Appl Radiat Isot 2010, 68:1709-1714.
28. 188Re at high labeling efficiency and specific radioactivity for tumor pretargeting. Appl Radiat Isot 2006, 64:971-978.
29. Liu G., Hnatowich D.J. A semiempirical model of tumor pretargeting. Biocojug Chem 2008, 19:2095-2104.
30. 111In improves MORF/cMORF pretargeting by reducing intestinal accumulation. Mol Image Biol 2009, 11:303-307.
31. Liu G., Dou S., Yin D., et al. A novel pretargeting method for measuring antibody internalization in tumor cells. Cancer Biother Radiopharm 2007, 22:33-39.
32. Nyman L.R., Wells K.S., Head W.S., et al. Real-time, multidimensional in vivo imaging used to investigate blood flow in mouse pancreatic islets. J Clin Invest 2008, 118:3790-3797.
33. Sweet I.R., Cook D.L., Lernmark A., Greenbaum C.J., Krohn K.A. Non-invasive imaging of beta cell mass: a quantitative analysis. Diabetes Technol Ther 2004, 6:652-659.